LBPO.ET04 · 实验与分子治疗 · Late-Breaking

Neoadjuvant chemotherapy induces clinically distinct spatial remodeling of the tumor microenvironment in PDAC

海报缩略图:Neoadjuvant chemotherapy induces clinically distinct spatial remodeling of the tumor microenvironment in PDAC
编号 LB477 展板 24 时间 4/22 09:00–12:00 区域 Section 53 主讲 Hyun Jung Kim, BS;MS;PhD
分会场 Late-Breaking Research: Experimental and Molecular Therapeutics 4
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Hyun Jung Kim1, Se Hui Jeong2, Sujie Lee3, Jung Kyoon Choi3, In Kyong Shim2, Kyung-Gon Kim1, Seung Mo Hong4, Woohyung Lee5, Do-hyun Park6, Seung-Jae Myung7, Chanho Park8, Seo Hye Park8, Dongjoo Lee8, Song Cheol Kim5

1Department of Medicine, University of Ulsan College of Medicine, Seoul, Korea, Republic of,2Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Republic of,3Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Deajeon, Korea, Republic of,4Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,5Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,6Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,7Digestive Disease Research Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,8Portrai, Inc., Seoul, Korea, Republic of

摘要 Abstract

Neoadjuvant chemotherapy (NACT) followed by surgical resection is increasingly becoming the standard treatment paradigm for pancreatic ductal adenocarcinoma (PDAC). However, post-surgical therapeutic strategies remain largely unguided by tumor. To address this critical gap, we performed an integrated multi-omics analysis using matched tumor specimens from the same clinical cohort (n=18 patients per group) to define how NACT reshapes stromal architecture and antitumor immunity in PDAC.Spatial transcriptomic analysis revealed pronounced NACT-induced reorganization of tumor and stromal compartments. Basal-like and classical-like tumor programs formed distinct spatial domains accompanied by heterogeneous CAF niches, including myCAF-, iCAF-, and apCAF-like regions. Although overall cellular composition was largely preserved, NACT triggered marked subtype-specific remodeling: basal-like tumors exhibited activation of inflammatory signaling, whereas classical-like tumors showed reduced KRAS signaling and epithelial-mesenchymal transition activity. In stromal compartments, myCAF-like regions displayed suppression of collagen biosynthesis and ECM organization programs, while iCAF- and apCAF-like niches retained inflammatory transcriptional states. Notably, NACT selectively increased spatial proximity between CD8⁺ T cells and classical-like tumor regions, whereas basal-like tumors remained embedded within CAF- and myeloid-enriched immune-restrictive microdomains.Proteomic profiling supported these spatial findings by demonstrating coordinated stromal reprogramming after NACT, with increased abundance of collagen- and coagulation-related proteins and reduced proliferative signatures. Cross-modal integration further revealed concordant activation of ECM remodeling pathways in CAF-rich niches and immune-modulatory programs near tumor regions. Consistently, multiplex immunohistochemistry demonstrated significantly increased infiltration of CD8⁺ cytotoxic and CD4⁺ helper T cells with enhanced proximity to malignant epithelial regions, while FOXP3⁺ regulatory T cells remained largely unchanged. Spatial immune organization was clinically relevant, as tumor proximity to activated CD8⁺ T cells predicted superior survival, whereas association with MDSC-dominant niches correlated with poor outcome.NACT therefore reshapes the PDAC microenvironment into clinically actionable spatial states, enabling post-surgical patient stratification and providing a rationale for personalized adjuvant strategies, including immunotherapy and CAF-targeted treatments strategy.
利益披露 Disclosure
H. Kim, None.. S. Jeong, None.. S. Lee, None.. J. Choi, None.. I. Shim, None.. K. Kim, None.. S. Hong, None.. W. Lee, None.. D. Park, None.. S. Myung, None.. C. Park, None.. S. Park, None.. D. Lee, None.. S. Kim, None.

在会议检索中打开